Financial compensation during recruitment did not improve consent rates for Alzheimer's disease study participants in this trial
A randomized controlled trial involving 320 analyzed participants from a highly educated sample investigated the impact of describing potential financial compensation during recruitment for an Alzheimer's disease study. The intervention group, which received this description, showed a lower consent rate than the control group where no compensation was mentioned. The primary outcome focused specifically on participant enrollment success.
Further analysis revealed that the consent rate in the intervention group was statistically lower than the control group in the per-protocol analysis. The effect size indicated a reduction of 12.72 points, with a p-value of 0.026. Other causal effect estimates also pointed toward lower enrollment in the compensated group, though statistical significance varied across different analytical approaches.
The study highlights a potential limitation where financial incentives might not work as expected for certain demographics. Researchers noted that compensation could affect individuals with lower socioeconomic status differently than the highly educated sample used here. These findings caution against assuming financial compensation universally improves recruitment in clinical trials.